Zacks: Brokerages Expect Global Blood Therapeutics Inc (GBT) Will Announce Earnings of -$0.73 Per Share
Wall Street analysts expect that Global Blood Therapeutics Inc (NASDAQ:GBT) will announce earnings per share (EPS) of ($0.73) for the current quarter, according to Zacks. Zero analysts have issued estimates for Global Blood Therapeutics’ earnings. The highest EPS estimate is ($0.66) and the lowest is ($1.00). Global Blood Therapeutics posted earnings of ($0.74) per share during the same quarter last year, which would suggest a positive year over year growth rate of 1.4%. The company is expected to announce its next quarterly earnings results on Monday, March 12th.
On average, analysts expect that Global Blood Therapeutics will report full-year earnings of ($2.55) per share for the current year, with EPS estimates ranging from ($2.82) to ($2.48). For the next financial year, analysts expect that the company will post earnings of ($2.99) per share, with EPS estimates ranging from ($3.54) to ($2.38). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Global Blood Therapeutics.
Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.04). During the same period in the prior year, the firm earned ($0.58) EPS.
In other news, VP Peter Radovich sold 12,500 shares of the firm’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $35.00, for a total value of $437,500.00. Following the sale, the vice president now directly owns 2,684 shares in the company, valued at approximately $93,940. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Charles J. Homcy sold 70,000 shares of the firm’s stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $33.97, for a total transaction of $2,377,900.00. Following the completion of the sale, the director now owns 83,328 shares in the company, valued at $2,830,652.16. The disclosure for this sale can be found here. Insiders have sold a total of 88,500 shares of company stock worth $3,003,350 in the last three months. Insiders own 5.30% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA boosted its holdings in shares of Global Blood Therapeutics by 694.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock valued at $124,000 after buying an additional 3,975 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Global Blood Therapeutics by 10.1% in the 1st quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock valued at $178,000 after buying an additional 440 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Global Blood Therapeutics in the 3rd quarter valued at about $200,000. Trexquant Investment LP bought a new stake in shares of Global Blood Therapeutics in the 3rd quarter valued at about $202,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Global Blood Therapeutics in the 3rd quarter valued at about $205,000. Institutional investors and hedge funds own 90.48% of the company’s stock.
Global Blood Therapeutics (NASDAQ:GBT) traded down $3.15 during mid-day trading on Tuesday, reaching $36.25. 3,960,441 shares of the company traded hands, compared to its average volume of 1,041,337. Global Blood Therapeutics has a 52 week low of $13.35 and a 52 week high of $45.85.
TRADEMARK VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/15/zacks-brokerages-expect-global-blood-therapeutics-inc-gbt-will-announce-earnings-of-0-73-per-share.html.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related stocks with our FREE daily email newsletter.